Where we are now in T-cell lymphoma is we only have two approved agents for relapse refractory T-cell lymphoma uh um across the board. We have pralatrexate and um um uh bilinostat. Um, we have Brenttuximabiddotin for relapsed anaplastic large cell lymphoma, um, but there's really a big on that need for the, you know, uh, a majority of patients with, with, uh, relapse or refractory T cell lymphoma, TFH and other subtypes. Um, so we have this quite good data from for T cell lymphoma, pretty large data set of over 100 patients and expansion of the phase two, with Duvali if showing about a 50% response rate, particularly higher, uh, for, uh, follicular helper angioreoblastic T cell lymphoma. So, um. Pretty confident that that's where the activity and that's where the efficacy is and then uh hopefully with the Turso or the randomized study um um opening and and and rolling and and eventually completing, uh, that we'll get standard use of Dubilii uh for relapse fracturey T cell lymphoma, that will be as a single agent. I think while that's going on, because we think it's an important agent or important activity, we and others are looking at a different combinations. I mentioned the combination with roxalitinib, uh, JAC inhibitor that we're, uh, studying. There's other studies going on in combination, um, with checkpoint inhibitors. I mentioned the upfront study in combination with chemotherapy run by the cooperative group, the Alliance. Uh, so hopefully as we get more standard use, we'll have more opportunity to explore and find its way to sort of uh find places where we can uh use it optimally to really benefit patients both in terms of disease control and hopefully either cures or bridges or bridges to curative therapy.
Presenter
